We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0L35 market cap is 8.5B. The company's latest EPS is USD -5.7295 and P/E is -21.69.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 380.83M | 540.1M | 701.89M | 933.01M | 1.24B |
| Operating Income | -705.56M | -564.16M | -459.71M | -536.2M | -267.82M |
| Net Income | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.82B | 2.98B | 3.15B | 3.13B | 3.26B |
| Total Liabilities | 1B | 2.22B | 2.22B | 2.74B | 2.41B |
| Total Equity | 818.19M | 761.76M | 928.01M | 384.95M | 859.34M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -456.46M | 107.47M | -443.17M | -325.35M | -500.99M |
| Investing | 286.73M | -121.72M | 495.41M | -1.05B | -165.8M |
| Financing | 642.55M | 682.32M | 561.57M | 232.51M | 125M |
| Market Cap | 8.5B |
| Price to Earnings Ratio | -21.69 |
| Price to Sales Ratio | 9.35 |
| Price to Cash Ratio | 27.13 |
| Price to Book Ratio | 13.53 |
| Dividend Yield | - |
| Shares Outstanding | 93.55M |
| Average Volume (1 week) | 11.8k |
| Average Volume (1 Month) | 2.46k |
| 52 Week Change | 0.00% |
| 52 Week High | 90.83 |
| 52 Week Low | 90.83 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Sarepta Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.sarepta.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
